Small animal imaging provides diverse methods for evaluating tumor growth and acute response to therapy. This study compared the utility of non-invasive optical and ultrasound imaging to monitor growth of three diverse human tumor xenografts (brain U87-luc-mCherry, mammary MCF7-luc-mCherry, and prostate PC3-luc) growing in nude mice. Bioluminescence imaging (BLI), fluorescence imaging (FLI), and Power Doppler ultrasound (PD US) were then applied to examine acute vascular disruption following administration of arsenic trioxide (ATO). During initial tumor growth, strong correlations were found between manual caliper measured tumor volume and FLI intensity, BLI intensity following luciferin injection, and traditional B-mode US. Administration of ATO to established U87 tumors caused significant vascular shutdown within 2 hrs at all doses in the range 5 to 10 mg/kg in a dose dependant manner, as revealed by depressed bioluminescent light emission. At lower doses substantial recovery was seen within 4 hrs. At 8 mg/kg there was >85% reduction in tumor vascular perfusion, which remained depressed after 6 hrs, but showed some recovery after 24 hrs. Similar response was observed in MCF7 and PC3 tumors. Dynamic BLI and PD US each showed similar duration and percent reductions in tumor blood flow, but FLI showed no significant changes during the first 24 hrs. The results provide further evidence for comparable utility of optical and ultrasound imaging for monitoring tumor growth, More specifically, they confirm the utility of BLI and ultrasound imaging as facile assays of the vascular disruption in solid tumors based on ATO as a model agent.
References
[1]
Thorpe PE (2004) Vascular Targeting Agents as Cancer Therapeutics. Clin Cancer Res 10: 415–427.
[2]
Mason RP, Zhao D, Liu L, Trawick ML, Pinney KG (2011) A Perspective on Vascular Disrupting Agents that Interact with Tubulin: Preclinical Tumor Imaging and Biological Assessment. Integrat Biol 3: 375–387.
[3]
Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nature Med 17: 1359–1370.
[4]
Lew YS, Kolozsvary A, Brown SL, Kim JH (2002) Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor. Cancer Res 62: 4202–4205.
[5]
Kim JH, Lew YS, Kolozsvary A, Ryu S, Brown SL (2003) Arsenic trioxide enhances radiation response of 9L glioma in the rat brain. Radiat Res 160: 662–666.
[6]
Griffin RJ, Monzen H, Williams BW, Park H, Lee SH, et al. (2003) Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours. Int J Hypertherm 19: 575–589.
[7]
Horsman MR, Siemann DW (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66: 11520–11539.
[8]
Murata R, Siemann DW, Overgaard J, Horsman MR (2001) Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res 156: 503–509.
[9]
Lee PC, Kakadiya R, Su TL, Lee TC (2010) Combination of Bifunctional Alkylating Agent and Arsenic Trioxide Synergistically Suppresses the Growth of Drug-Resistant Tumor Cells. Neoplasia 12: 376-U372.
[10]
McKeage MJ, Baguley BC (2010) Disrupting Established Tumor Blood Vessels An Emerging Therapeutic Strategy for Cancer. Cancer 116: 1859–1871.
[11]
Contag CH, Ross BD (2002) It's not just about anatomy: In vivo bioluminescence imaging as an eyepiece into biology. JMRI 16: 378–387.
[12]
Prescher JA, Contag CH (2010) Guided by the light: visualizing biomolecular processes in living animals with bioluminescence. Curr Opin Chem Biol 14: 80–89.
[13]
O'Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT (2009) Bioluminescent imaging: a critical tool in pre-clinical oncology research. J Pathol 220: 317–327.
[14]
Goertz DE, Yu JL, Kerbel RS, Burns PN, Foster FS (2002) High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res 62: 6371–6375.
[15]
Paroo Z, Bollinger RA, Braasch DA, Richer E, Corey DR, et al. (2004) Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. Molecular Imaging 3: 117–124.
[16]
Zhao D, Richer E, Antich PP, Mason RP (2008) Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging (BLI) and confirmed by magnetic resonance imaging (MRI). FASEB J 22: 2445–2451.
[17]
Gee MS, Saunders HM, Lee JC, Sanzo JF, Jenkins WT, et al. (2001) Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations. Cancer Res 61: 2974–2982.
[18]
Pinter SZ, Lacefield JC (2009) Detectability of Small Blood Vessels with High-Frequency Power Doppler and Selection of Wall Filter Cut-Off Velocity for Microvascular Imaging. Ultrasound Med Biol 35: 1217–1228.
[19]
Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH (1999) Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 59: 6033–6037.
[20]
Contero A, Richer E, Gondim A, Mason RP (2009) High-throughput quantitative bioluminescence imaging for assessing tumor burden. Methods Mol Biol 574: 37–45.
[21]
Choy G, O'Connor S, Diehn FE, Costouros N, Alexander HR, et al. (2003) Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. Biotechniques 35: 1022-+.
[22]
Caceres G, Xiao YZU, Jiao JA, Zankina R, Aller A, et al. (2003) Imaging of luciferase and GFP-transfected human tumours in nude mice. Luminescence 18: 218–223.
[23]
Sarraf-Yazdi S, Mi J, Dewhirst MW, Clary BM (2004) Use of in vivo bioluminescence imaging to predict hepatic tumor burden in mice. J Surg Res 120: 249–255.
[24]
Ayers GD, McKinley ET, Zhao P, Fritz JM, Metry RE, et al. (2010) Volume of Preclinical Xenograft Tumors Is More Accurately Assessed by Ultrasound Imaging Than Manual Caliper Measurements. J Ultrasound Med 29: 891–901.
[25]
Hines-Peralta A, Sukhatme V, Regan M, Signoretti S, Liu ZJ, et al. (2006) Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. Radiology 240: 82–89.
[26]
Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, et al. (2002) Arsenic trioxide and breast cancer: Analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 73: 61–73.
[27]
Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, et al. (2001) Tumor Growth Inhibition by Arsenic Trioxide (As2O3) in the Orthotopic Metastasis Model of Androgen-independent Prostate Cancer. Cancer Res 61: 5432–5440.
[28]
Ning S, Knox SJ (2006) Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma. Internat J Radiat Oncol Biol Phys 65: 493–498.
[29]
Griffin RJ, Lee SH, Rood KL, Stewart MJ, Lyons JC, et al. (2000) Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors. Neoplasia 2: 555–560.
[30]
Griffin RJ, Williams BW, Park HJ, Song CW (2005) Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy. Internat J Radiat Oncol Biol Phys 61: 1516–1522.
[31]
Bollinger RA (2006) Evaluation of the Light Emission Kinetics in Luciferin/Luciferase-Based In Vivo Bioluminescence Imaging for Guidance in the Development of Small Animal Imaging Study Design Dallas: UT Southwestern.
[32]
Keyaerts M, Verschueren J, Bos TJ, Tchouate-Gainkam LO, Peleman C, et al. (2008) Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D-luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Molec Imaging 35: 999–1007.
[33]
Diepart C, Karroum O, Magat J, Feron O, Verrax J, et al. (2012) Arsenic Trioxide Treatment Decreases the Oxygen Consumption Rate of Tumor Cells and Radiosensitizes Solid Tumors. Cancer Res 72: 482–490.
[34]
Maye P, Fu Y, Butler DL, Chokalingam K, Liu YL, et al. (2011) Generation and Characterization of Col10a1-mCherry Reporter Mice. Genesis 49: 410–418.
[35]
Su X, Liu L, Lin M, Gondim A, Mason RP. Assessing vascular targeting agents using dynamic fluorescent contrast in vivo; 2009; Denver, CO pp. 5018.
[36]
Murgo AJ (2001) Clinical trials of arsenic trioxide in hematologic and solid tumors: Overview of the national cancer institute cooperative research and development studies. Oncologist 6: 22–28.
[37]
Park JH, Tallman MS (2011) Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible? Exp Rev Hematol 4: 427–436.
[38]
Ahn RW, Chen F, Chen H, Stern ST, Clogston JD, et al. (2010) A Novel Nanoparticulate Formulation of Arsenic Trioxide with Enhanced Therapeutic Efficacy in a Murine Model of Breast Cancer. Clin Cancer Res 16: 3607–3617.
[39]
Yu H, Zhu G-Y, Xu R-Z, Niu H-Z, Lu Q, et al. (2011) Arterial Embolization Hyperthermia Using As2O3 Nanoparticles in VX2 Carcinoma Induced Liver Tumors. PLoS ONE 6: e17926.
[40]
Magnusson J, Trawick M, Pinney K, Mason RP, Liu L (2011) Assessment of Antivascular Effects of KGP265 in Breast Cancer using Dynamic Bioluminescence. Austin, TX.
[41]
Liu L, Beck H, Wang X, Hsieh H-P, Mason RP, et al. (2012) Tubulin-Destabilizing Agent BPR0L075 Induces Vascular-Disruption in Human Breast Cancer Mammary Fat Pad Xenografts. PLoS ONE accepted 2012.
